secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001789769-24-000018
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio closes UK manufacturing, cuts 61% workforce; collaborator to conduct ITIL-306 feasibility studies
--------------------------------------------------------------------------------

- Board approved closure of UK manufacturing and clinical operations; UK workforce reduced by ~61%.
- Restructuring costs estimated up to $6.1M for severance and contract terminations; expect completion H1 2024.
- No longer expects to report clinical data from ITIL-306-202 trial in 2024.
- Entered agreement with collaborator for preclinical feasibility studies of ITIL-306 in NSCLC; potential IIT in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/0001789769-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/til-20240114.htm
  HTML page:      https://secwatch.observer/filing/0001789769-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer